Lung cancer trial uses genetic 'Leftovers' to guide smarter immunotherapy

NCT ID NCT07120698

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with stage II-IIIB non-small cell lung cancer whose tumors did not fully disappear after initial chemotherapy plus immunotherapy. Researchers will use a blood test to look for tiny bits of cancer DNA (called MRD) to decide if additional immunotherapy with sintilimab is needed. The goal is to see if this personalized approach can help prevent the cancer from coming back. About 115 adults will take part across two hospitals in China.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bilateral multicystic dysplastic kidney non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, Guangdong, 510080, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The third people's hospital of chengdu

    RECRUITING

    Chengdu, Sichuan, 610031, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••